Abstract

Acute promyelocytic leukemia (APL) is a severe type of acute leukemia and the prognosis of patients was poor. Indirubin is the active constituent of the traditional Chinese medicine qingdai and an indoline anti-tumor drug. N’-Acetylindirubin is a novel indirubin derivative with better curative effect and less side effect. In this study, the effects of N’-Acetylindirubin on proliferation, apoptosis and cell cycle of acute myeloid leukemia cell line HL-60 was examined. The results demonstrated that N’-Acetylindirubin significantly induced apoptotic cell death in a dose and time-dependent manner and arrested cell cycle in G2/M in HL-60 cells. N’-Acetylindirubin also suppressed cyclin D1. This study suggests that N’-Acetylindirubin may serves as a potential chemopreventive agent for acute promyelocytic leukemia.

Highlights

  • Acute promyelocytic leukemia (APL) is a severe type of acute leukemia and the treatment is mainly chemotherapy and radiotherapy

  • Indirubin is the active constituent of the traditional Chinese medicine qingdai and an indoline anti-tumor drug

  • The results showed that N’-Acetylindirubin inhibited the proliferation of HL-60 cells in dose- and time-dependent manners (Table 1)

Read more

Summary

Introduction

Acute promyelocytic leukemia (APL) is a severe type of acute leukemia and the treatment is mainly chemotherapy and radiotherapy. The drugs commonly used in chemotherapy have many side effects and the prognosis of patients was still poor. The search for new anticancer compounds in foods or plant medicines is a realistic and promising approach to the prevention and treatment of cancer. Yu chronic myelogenous leukemia [2]. The clinical trial was used to treat chronic myeloid leukemia, and its curative effect was better than indirubin and the side effect was less. HL-60 cells were used to observe the anti-tumor effect and its mechanism of N’-Acetylindirubin

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call